Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients

E Walter, M Voit, G Eichhober - Expert Review of …, 2021 - Taylor & Francis
Objectives Several direct oral anticoagulants (DOACs) have been approved by the
European Medicines Agency since 2008. The aim of the present cost-effectiveness-analysis …
被引用次数：7 相关文章

Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients.

E Walter, M Voit, G Eichhober - Expert Review of …, 2020 - europepmc.org
Objectives Several direct oral anticoagulants (DOACs) have been approved by the
European Medicines Agency since 2008. The aim of the present cost-effectiveness-analysis …

Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients

E Walter, M Voit, G Eichhober - Expert review of …, 2021 - pubmed.ncbi.nlm.nih.gov
Objectives Several direct oral anticoagulants (DOACs) have been approved by the
European Medicines Agency since 2008. The aim of the present cost-effectiveness-analysis …